Galderma revenue rises 25.1% to $4.765 billion in nine months
Key Facts
Galderma posted net sales of $4.765 billion in the first nine months of 2026, up 25.1% at constant currency, according to the company’s results. It said growth came mainly from higher volume, with a positive contribution from product mix. The results come as investors track L’Oréal’s stake in the company, but available data does not confirm a new announcement on November 19, 2026, about doubling the stake. The latest available developments therefore center on Galderma’s operating performance and annual outlook, not on a new deal confirmed on the day of the story.
Growth was spread across the company’s three businesses, with therapeutic dermatology posting the fastest increase during the period. Sales in that business rose 64.4% at constant currency in the first nine months of 2026. Dermatological skincare sales increased 16.2%, while injectable aesthetics grew 13.2%. The figures show a clear difference in expansion rates among Galderma’s businesses, with therapeutic dermatology outpacing the other two. The company attributed overall sales growth mainly to volume, alongside what it described as a positive product mix.
On October 22, 2026, Galderma raised its full-year net sales growth outlook to a range of 22.5% to 23.5% at constant currency, from a previous range of 19% to 21%. It maintained its forecast for core EBITDA margin at about 26% on the same basis. The growth range revision raises the annual estimate compared with previous guidance, while the company kept its core margin forecast unchanged. The company links its outlook to sales performance during the year, which showed growth across all three businesses in the first nine months. The guidance provides a framework for assessing the expected full-year results, without changing the fact that it was announced in October.
L’Oréal’s stake in Galderma came into focus in a deal announced on December 8, 2025, which was completed in February 2026. When the deal was announced, Galderma shares rose 3.4% in an initial reaction, while L’Oréal shares fell 1.6%, according to Reuters via Investing.com. In the valuation context at the time, Bloomberg said a 10% stake was worth about 3.9 billion Swiss francs, or 4.9 billion dollars, based on Galderma’s closing price on the Friday before the announcement. Those figures are tied to market conditions when the deal was announced in December 2025. Available trading data for L’Oréal shares under the ticker LRLCY shows a close of $97.05 on November 18, 2026.
Alongside growth in its business, Galderma announced an agreement to acquire ZO Skin Health in an all-cash deal with an enterprise value of $1.5 billion. The company said in its statement that the acquisition is expected to close in the fourth quarter of 2026 or early 2027, subject to approvals. The agreement puts the expected closing date among the upcoming developments related to Galderma’s business. It also follows the company’s October increase to its annual sales growth outlook, after the first nine months’ results. The next specified step in the available information is completion of the ZO deal within the timetable announced by the company.